Tumors/Nonsarcoma Clinical Studies

Some of the many Hematology/Oncology research opportunities available related to sarcomas, including bone tumors and certain soft tissue tumors, are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies


M0 Medulloblastoma Treatment in Very Young Children – Phase I

Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas

Read more

Melanoma Treatment with Combination Binimetinib & Encorafenib – Phase Ib

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma

Read more

Pediatric Tumors and Specimen Study

A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors

Read more

Solid Tumor or ALCL Treatment with Crizotinib and Conventional Chemotherapy – Phase I

Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Read more

Solid Tumor Treatment with MK-1775 – Phase I/II

MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Read more

Solid Tumor Treatment with Ramucirumab – Phase I

A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors

Read more

Tumor and Acute Lymphoblastic Leukemia Treatment with BMN 673 and Temozolomide – Phase I/II

BMN 673, an Oral Poly Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

Read more

Tumor Treatment with Nivolumab with and without Ipilimumab – Phase I/II

Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Read more

Wilms Tumor Treatment with Combination Chemotherapy and Surgery – Phase III

Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor

Read more